乳腺癌治疗和生物标志物的最新进展:机制和临床意义。

IF 2.6 4区 医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Arbab Husain, Hamda Khan, Jamale E Fatima, Shirjeel Ahmad Siddiqui, Akash Deep Singh, Adil Husain, Shivam Pandey, Ravi Kant, Afreen Khanam, Pratibha Pandey, Fahad Khan
{"title":"乳腺癌治疗和生物标志物的最新进展:机制和临床意义。","authors":"Arbab Husain, Hamda Khan, Jamale E Fatima, Shirjeel Ahmad Siddiqui, Akash Deep Singh, Adil Husain, Shivam Pandey, Ravi Kant, Afreen Khanam, Pratibha Pandey, Fahad Khan","doi":"10.2174/0113892010343901250204054241","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer remains a critical health concern, requiring continual innovation in treatment to improve patient outcomes. The continuous obstacles in therapy and the need for novel techniques underline the importance of making advances in this discipline. Precision medicine has emerged as a viable method, with genomic profiling and molecular subtyping allowing for targeted therapy based on distinct breast cancer subtypes. This strategy is supplemented by advances in early detection and screening, with technologies like liquid biopsy promising earlier and more accurate diagnosis. The introduction of immunotherapy has transformed breast cancer treatment by using the body's immune system to combat cancer. Recent discoveries, particularly combination medicines, attempt to circumvent resistance mechanisms and improve treatment success. Furthermore, including lifestyle therapies such as nutrition, exercise, and psychological support has been demonstrated to reduce breast cancer risk and strengthen survivability rates. Survivorship programs serve an important role in comprehensive care by addressing long-term needs and enhancing survivors' quality of life. Investigating innovative therapeutic approaches, such as developing cancer vaccines, epigenetic modulators, and RNA interference (RNAi) therapy, provides new treatment options. Fostering collaboration among healthcare personnel through shared decision-making and tumor committees is essential for the integration of multidisciplinary care, which ensures patientcentered care. Although advancements have been made, there are still numerous obstacles to overcome in the implementation of these future directions. To effectively confront these obstacles, it is imperative to capitalize on opportunities for innovation and collaboration. It is imperative to address ethical, social, and economic factors in the advancement of breast cancer care to ensure that innovations are equitable and accessible. In conclusion, the future of breast cancer management is bright since substantial improvements are on the verge of turning patient treatment into a completely different experience. For these breakthroughs to become a reality, it is necessary to maintain research efforts, advocate for them, and work together. The dedication to innovation and the joint effort to overcome current problems are the two important factors that will determine whether or not breast cancer treatment and surviving will have a better future.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recent Advancements in Breast Cancer Therapies and Biomarkers: Mechanisms and Clinical Significance.\",\"authors\":\"Arbab Husain, Hamda Khan, Jamale E Fatima, Shirjeel Ahmad Siddiqui, Akash Deep Singh, Adil Husain, Shivam Pandey, Ravi Kant, Afreen Khanam, Pratibha Pandey, Fahad Khan\",\"doi\":\"10.2174/0113892010343901250204054241\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Breast cancer remains a critical health concern, requiring continual innovation in treatment to improve patient outcomes. The continuous obstacles in therapy and the need for novel techniques underline the importance of making advances in this discipline. Precision medicine has emerged as a viable method, with genomic profiling and molecular subtyping allowing for targeted therapy based on distinct breast cancer subtypes. This strategy is supplemented by advances in early detection and screening, with technologies like liquid biopsy promising earlier and more accurate diagnosis. The introduction of immunotherapy has transformed breast cancer treatment by using the body's immune system to combat cancer. Recent discoveries, particularly combination medicines, attempt to circumvent resistance mechanisms and improve treatment success. Furthermore, including lifestyle therapies such as nutrition, exercise, and psychological support has been demonstrated to reduce breast cancer risk and strengthen survivability rates. Survivorship programs serve an important role in comprehensive care by addressing long-term needs and enhancing survivors' quality of life. Investigating innovative therapeutic approaches, such as developing cancer vaccines, epigenetic modulators, and RNA interference (RNAi) therapy, provides new treatment options. Fostering collaboration among healthcare personnel through shared decision-making and tumor committees is essential for the integration of multidisciplinary care, which ensures patientcentered care. Although advancements have been made, there are still numerous obstacles to overcome in the implementation of these future directions. To effectively confront these obstacles, it is imperative to capitalize on opportunities for innovation and collaboration. It is imperative to address ethical, social, and economic factors in the advancement of breast cancer care to ensure that innovations are equitable and accessible. In conclusion, the future of breast cancer management is bright since substantial improvements are on the verge of turning patient treatment into a completely different experience. For these breakthroughs to become a reality, it is necessary to maintain research efforts, advocate for them, and work together. The dedication to innovation and the joint effort to overcome current problems are the two important factors that will determine whether or not breast cancer treatment and surviving will have a better future.</p>\",\"PeriodicalId\":10881,\"journal\":{\"name\":\"Current pharmaceutical biotechnology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical biotechnology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113892010343901250204054241\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010343901250204054241","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

乳腺癌仍然是一个严重的健康问题,需要在治疗方面不断创新,以改善患者的预后。治疗中的持续障碍和对新技术的需求强调了在这一学科中取得进展的重要性。精准医学已经成为一种可行的方法,基因组分析和分子分型使得基于不同乳腺癌亚型的靶向治疗成为可能。这一战略还得到了早期检测和筛查方面的进步的补充,液体活检等技术有望更早、更准确地诊断。免疫疗法的引入改变了乳腺癌的治疗方法,利用人体的免疫系统来对抗癌症。最近的发现,特别是联合药物,试图绕过耐药机制并提高治疗成功率。此外,包括营养、运动和心理支持等生活方式疗法已被证明可以降低乳腺癌风险并提高生存率。通过解决长期需求和提高幸存者的生活质量,幸存者项目在全面护理中发挥着重要作用。研究创新的治疗方法,如开发癌症疫苗、表观遗传调节剂和RNA干扰(RNAi)疗法,提供了新的治疗选择。通过共享决策和肿瘤委员会促进医护人员之间的协作对于多学科护理的整合至关重要,这确保了以患者为中心的护理。虽然取得了进展,但在执行这些未来方向方面仍有许多障碍需要克服。为了有效地应对这些障碍,必须利用创新和合作的机会。必须解决促进乳腺癌治疗的伦理、社会和经济因素,以确保创新的公平性和可及性。总之,乳腺癌管理的未来是光明的,因为实质性的改进即将使患者的治疗变成一种完全不同的体验。为了使这些突破成为现实,有必要保持研究努力,倡导它们,共同努力。致力于创新和共同努力克服当前的问题是决定乳腺癌治疗和生存是否会有一个更好的未来的两个重要因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Recent Advancements in Breast Cancer Therapies and Biomarkers: Mechanisms and Clinical Significance.

Breast cancer remains a critical health concern, requiring continual innovation in treatment to improve patient outcomes. The continuous obstacles in therapy and the need for novel techniques underline the importance of making advances in this discipline. Precision medicine has emerged as a viable method, with genomic profiling and molecular subtyping allowing for targeted therapy based on distinct breast cancer subtypes. This strategy is supplemented by advances in early detection and screening, with technologies like liquid biopsy promising earlier and more accurate diagnosis. The introduction of immunotherapy has transformed breast cancer treatment by using the body's immune system to combat cancer. Recent discoveries, particularly combination medicines, attempt to circumvent resistance mechanisms and improve treatment success. Furthermore, including lifestyle therapies such as nutrition, exercise, and psychological support has been demonstrated to reduce breast cancer risk and strengthen survivability rates. Survivorship programs serve an important role in comprehensive care by addressing long-term needs and enhancing survivors' quality of life. Investigating innovative therapeutic approaches, such as developing cancer vaccines, epigenetic modulators, and RNA interference (RNAi) therapy, provides new treatment options. Fostering collaboration among healthcare personnel through shared decision-making and tumor committees is essential for the integration of multidisciplinary care, which ensures patientcentered care. Although advancements have been made, there are still numerous obstacles to overcome in the implementation of these future directions. To effectively confront these obstacles, it is imperative to capitalize on opportunities for innovation and collaboration. It is imperative to address ethical, social, and economic factors in the advancement of breast cancer care to ensure that innovations are equitable and accessible. In conclusion, the future of breast cancer management is bright since substantial improvements are on the verge of turning patient treatment into a completely different experience. For these breakthroughs to become a reality, it is necessary to maintain research efforts, advocate for them, and work together. The dedication to innovation and the joint effort to overcome current problems are the two important factors that will determine whether or not breast cancer treatment and surviving will have a better future.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current pharmaceutical biotechnology
Current pharmaceutical biotechnology 医学-生化与分子生物学
CiteScore
5.60
自引率
3.60%
发文量
203
审稿时长
6 months
期刊介绍: Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include: DNA/protein engineering and processing Synthetic biotechnology Omics (genomics, proteomics, metabolomics and systems biology) Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes) Drug delivery and targeting Nanobiotechnology Molecular pharmaceutics and molecular pharmacology Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes) Pharmacokinetics and pharmacodynamics Applied Microbiology Bioinformatics (computational biopharmaceutics and modeling) Environmental biotechnology Regenerative medicine (stem cells, tissue engineering and biomaterials) Translational immunology (cell therapies, antibody engineering, xenotransplantation) Industrial bioprocesses for drug production and development Biosafety Biotech ethics Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信